{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:00:18Z","timestamp":1793833218828,"version":"4.6.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100000926","name":"Leukaemia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12967-016-0994-6","type":"journal-article","created":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T23:12:40Z","timestamp":1473117160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5222-0433","authenticated-orcid":false,"given":"Rachel E.","family":"Cooke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Gherardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale I.","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Koldej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,6]]},"reference":[{"key":"994_CR1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blad\u00e9 J, Merlini G, Mateos M-V, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"994_CR2","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet. 2015;385:2197\u2013208.","journal-title":"Lancet"},{"key":"994_CR3","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113:5418\u201322.","journal-title":"Blood"},{"key":"994_CR4","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412\u20137.","journal-title":"Blood"},{"key":"994_CR5","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1080\/10428190802464729","volume":"49","author":"SJ Harrison","year":"2009","unstructured":"Harrison SJ, Franklin IM, Campbell JDM. Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy. Leuk Lymphoma. 2009;49:2272\u201383.","journal-title":"Leuk Lymphoma"},{"key":"994_CR6","unstructured":"Quach HA. The clinical role of novel biological agents and the in vivo immunological effects of immunomodulatory drugs (IMiDs) in the management of multiple myeloma. PhD Thesis, University of Melbourne; 2010. https:\/\/minerva-access.unimelb.edu.au\/handle\/11343\/35485 ."},{"key":"994_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2217\/imt.10.9","volume":"2","author":"DS Ritchie","year":"2010","unstructured":"Ritchie DS, Quach H, Fielding K, Neeson P. Drug-mediated and cellular immunotherapy in multiple myeloma. Immunotherapy. 2010;2(2):243\u201355. doi: 10.2217\/imt.10.9","journal-title":"Immunotherapy"},{"key":"994_CR8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4161\/onci.18963","volume":"1","author":"A Hsu","year":"2012","unstructured":"Hsu A, Ritchie DS, Neeson P. Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone? Oncoimmunology. 2012;1:372\u20134.","journal-title":"Oncoimmunology"},{"key":"994_CR9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","volume":"138","author":"G Pratt","year":"2007","unstructured":"Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007;138:563\u201379.","journal-title":"Br J Haematol"},{"key":"994_CR10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-4933-5-6","volume":"5","author":"S Koch","year":"2008","unstructured":"Koch S, Larbi A, Derhovanessian E, \u00d6zcelik D, Naumova E, Pawelec G. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing. 2008;5:6.","journal-title":"Immun Ageing"},{"key":"994_CR11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1084\/jem.20050341","volume":"201","author":"J Nikolich-\u017dugich","year":"2005","unstructured":"Nikolich-\u017dugich J. T cell aging: naive but not young. J Exp Med. 2005;201:837\u201340.","journal-title":"J Exp Med"},{"key":"994_CR12","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1182\/blood-2011-03-339879","volume":"118","author":"SJ Harrison","year":"2011","unstructured":"Harrison SJ, Quach H, Link E, Seymour JF, Ritchie DS, Ruell S, Dean J, Januszewicz H, Johnstone R, Neeson P, Dickinson M, Nichols J, Prince HM. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood. 2011;118:6274\u201383.","journal-title":"Blood"},{"key":"994_CR13","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125:3049\u201358.","journal-title":"Blood"},{"key":"994_CR14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/imr.12166","volume":"259","author":"PA Savage","year":"2014","unstructured":"Savage PA, Leventhal DS, Malchow S. Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol Rev. 2014;259:245\u201358.","journal-title":"Immunol Rev"},{"key":"994_CR15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","volume":"13","author":"M Chesi","year":"2008","unstructured":"Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, Valdez R, Palmer SE, Haas SS, Stewart AK, Fonseca R, Kremer R, Cattoretti G, Bergsagel PL. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008;13:167\u201380.","journal-title":"Cancer Cell"},{"key":"994_CR16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","volume":"120","author":"M Chesi","year":"2012","unstructured":"Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M, Stewart AK, Johnstone RW, Bergsagel PL. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood. 2012;120:376\u201385.","journal-title":"Blood"},{"key":"994_CR17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","volume":"2","author":"WM Kuehl","year":"2002","unstructured":"Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175\u201387.","journal-title":"Nat Rev Cancer"},{"key":"994_CR18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ccr.2008.01.022","volume":"13","author":"WM Kuehl","year":"2008","unstructured":"Kuehl WM. Modeling multiple myeloma by aid-dependent conditional activation of MYC. Cancer Cell. 2008;13:85\u20137.","journal-title":"Cancer Cell"},{"key":"994_CR19","doi-asserted-by":"crossref","first-page":"e1008850","DOI":"10.1080\/2162402X.2015.1008850","volume":"4","author":"A Calcinotto","year":"2015","unstructured":"Calcinotto A, Ponzoni M, Ria R, Grioni M, Cattaneo E, Villa I, Sabrina Bertilaccio MT, Chesi M, Rubinacci A, Tonon G, Bergsagel PL, Vacca A, Bellone M. Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. Oncoimmunology. 2015;4:e1008850.","journal-title":"Oncoimmunology"},{"key":"994_CR20","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/ajh.23234","volume":"87","author":"H Quach","year":"2012","unstructured":"Quach H, Kalff A, Spencer A. Lenalidomide in multiple myeloma: current status and future potential. Am J Hematol. 2012;87:1089\u201395.","journal-title":"Am J Hematol"},{"key":"994_CR21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.critrevonc.2015.06.006","volume":"96","author":"AO Ayed","year":"2015","unstructured":"Ayed AO, Chang L-J, Moreb JS. Immunotherapy for multiple myeloma: current status and future directions. Crit Rev Oncol Hematol. 2015;96:399\u2013412.","journal-title":"Crit Rev Oncol Hematol"},{"key":"994_CR22","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.exphem.2015.04.010","volume":"43","author":"N Mimura","year":"2015","unstructured":"Mimura N, Hideshima T, Anderson KC. Novel therapeutic strategies for multiple myeloma. Exp Hematol. 2015;43:732\u201341.","journal-title":"Exp Hematol"},{"key":"994_CR23","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582\u201390.","journal-title":"N Engl J Med"},{"key":"994_CR24","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","volume":"120","author":"JJ Keats","year":"2012","unstructured":"Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120:1067\u201376.","journal-title":"Blood"},{"key":"994_CR25","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood-2010-04-278432","volume":"117","author":"AK Hsu","year":"2011","unstructured":"Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, Smyth MJ, Neeson P, Ritchie DS. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117:1605\u201313.","journal-title":"Blood"},{"key":"994_CR26","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2008-03-143222","volume":"112","author":"KM Dhodapkar","year":"2008","unstructured":"Dhodapkar KM, Barbuto S, Matthews P, Kukreja A, Mazumder A, Vesole D, Jagannath S, Dhodapkar MV. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood. 2008;112:2878\u201385.","journal-title":"Blood"},{"key":"994_CR27","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","volume":"116","author":"K Noonan","year":"2010","unstructured":"Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood. 2010;116:3554\u201363.","journal-title":"Blood"},{"key":"994_CR28","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","volume":"115","author":"RH Prabhala","year":"2010","unstructured":"Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, Ghobrial IM, Treon SP, Daley JF, Anderson KC, Kutok JL, Munshi NC. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010;115:5385\u201392.","journal-title":"Blood"},{"key":"994_CR29","first-page":"1680","volume":"19","author":"JP Chou","year":"2013","unstructured":"Chou JP, Effros RB. T cell replicative senescence in human aging. Curr Pharm Des. 2013;19:1680\u201398.","journal-title":"Curr Pharm Des"},{"key":"994_CR30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/sji.12413","volume":"83","author":"R Valiathan","year":"2016","unstructured":"Valiathan R, Ashman M, Asthana D. Effects of ageing on the immune system: infants to elderly. Scand J Immunol. 2016;83:255\u201366.","journal-title":"Scand J Immunol"},{"key":"994_CR31","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399.","journal-title":"Nat Rev Immunol"},{"key":"994_CR32","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V98.9.2817","volume":"98","author":"DMY Sze","year":"2001","unstructured":"Sze DMY. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28\u2212 compartment. Blood. 2001;98:2817\u201327.","journal-title":"Blood"},{"key":"994_CR33","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/bcj.2013.34","volume":"3","author":"C Bryant","year":"2013","unstructured":"Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, Gibson J, Ho PJ, Iland H, Fromm P, Woodland N, Nassif N, Hart D, Joshua DE. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance. Blood Cancer J. 2013;3:e148.","journal-title":"Blood Cancer J"},{"key":"994_CR34","first-page":"2026","volume":"65","author":"K Noonan","year":"2005","unstructured":"Noonan K, Matsui W, Serafini P, Carbley R, Tan G, Khalili J, Bonyhadi M, Levitsky H, Whartenby K, Borrello I. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Cell. 2005;65:2026\u201334.","journal-title":"Cancer Cell"},{"key":"994_CR35","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1172\/JCI77181","volume":"125","author":"C Guillerey","year":"2015","unstructured":"Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MCR, Teng MWL, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, Smyth MJ, Martinet L. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest. 2015;125:2077\u201389.","journal-title":"J Clin Invest"},{"key":"994_CR36","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","volume":"102","author":"CA Klebanoff","year":"2005","unstructured":"Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP. Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA. 2005;102:9571\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"994_CR37","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI24480","volume":"115","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni L. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115:1616\u201326.","journal-title":"J Clin Invest"},{"key":"994_CR38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2015-02-626754","volume":"126","author":"F McClanahan","year":"2015","unstructured":"McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, Croce CM, Capasso M, Gribben JG. Mechanisms of PD-L1\/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E\u00b5-TCL1 CLL mouse model. Blood. 2015;126:212\u201321.","journal-title":"Blood"},{"key":"994_CR39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, G\u00fctgemann I, Eilers M, Felsher DW. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227\u201331.","journal-title":"Science"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-016-0994-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:03:10Z","timestamp":1498327390000},"score":1,"resource":{"primary":{"URL":"http:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-016-0994-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,6]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["994"],"URL":"https:\/\/doi.org\/10.1186\/s12967-016-0994-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,6]]},"article-number":"259"}}